212 related articles for article (PubMed ID: 30747109)
1. Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis.
Tang B; Wang J; Luo LL; Li QG; Huang D
Med Sci Monit; 2019 Feb; 25():1155-1163. PubMed ID: 30747109
[TBL] [Abstract][Full Text] [Related]
2. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
3. Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis.
Tang B; Wang J; Luo LL; Li QG; Huang D
Int J Chron Obstruct Pulmon Dis; 2019; 14():757-766. PubMed ID: 31015757
[TBL] [Abstract][Full Text] [Related]
4. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Szafranski W; Cukier A; Ramirez A; Menga G; Sansores R; Nahabedian S; Peterson S; Olsson H
Eur Respir J; 2003 Jan; 21(1):74-81. PubMed ID: 12570112
[TBL] [Abstract][Full Text] [Related]
6. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
[TBL] [Abstract][Full Text] [Related]
7. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
8. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Cates CJ; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2004; (3):CD003794. PubMed ID: 15266502
[TBL] [Abstract][Full Text] [Related]
9. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
10. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
[TBL] [Abstract][Full Text] [Related]
11. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
12. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.
Corren J; Korenblat PE; Miller CJ; O'Brien CD; Mezzanotte WS
Clin Ther; 2007 May; 29(5):823-843. PubMed ID: 17697902
[TBL] [Abstract][Full Text] [Related]
13. Budesonide/formoterol: in chronic obstructive pulmonary disease.
Reynolds NA; Perry CM; Keating GM
Drugs; 2004; 64(4):431-41; discussion 433-4. PubMed ID: 14969576
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD.
Williamson PA; Short PM; Clearie KL; Vaidyanathan S; Fardon TC; Howaniec LJ; Lipworth BJ
Chest; 2010 Sep; 138(3):595-604. PubMed ID: 20418370
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
Löfdahl CG; Ericsson A; Svensson K; Andreasson E
Pharmacoeconomics; 2005; 23(4):365-75. PubMed ID: 15853436
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
Calverley PM; Boonsawat W; Cseke Z; Zhong N; Peterson S; Olsson H
Eur Respir J; 2003 Dec; 22(6):912-9. PubMed ID: 14680078
[TBL] [Abstract][Full Text] [Related]
20. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]